Early Chemotherapy Combining Taxotere (Docetaxel) with Hormone Therapy Recommended for Metastaic Prostate Cancer.

A new large clinical trial suggests that survival can be improved in men with metastatic prostate cancer with the addition of docetaxel® chemotherapy to frontline hormonal therapy. Treatment-naive men with advanced prostate cancer who received both docetaxel and hormonal therapy lived an average of 10 months longer compared with men who were treated with hormonal therapy alone.  For details, see the following link.  This has also been  discussed in a previous website post dated September 20th, 2014.®